ALK and non-small cell lung carcinoma: Alectinib was approved for the treatment of ALK-positive NSCLC in Japan at a dose of 300 mg twice daily on the basis of results of the single-arm phase 1-2 AF-001JP study (JapicCTI-101264) in ALK inhibitor-naïve Japanese patients.4